Ultralow Dose PET Imaging for PSMA Expression
Trial statusRecruiting
Trial phasePhase 2
Trial typeInterventional
Biological sexAll
Age18-120
SponsorAkiva Mintz
About this trial
The goal of this clinical trial is to evaluate an investigational ultralow dose PET imaging technique for prostate cancer detection and monitoring. The main question it aims to answer is:
Can the investigators optimize the timing, scan duration, and image reconstruction to reduce the radiation dose 10-100 fold of the current clinical standard?
Participants will be injected with a radioactive tracer called 18F-DCFPyL and be imaged on a new type of high sensitivity PET scanner for up to 3 hours
Eligibility criteria
Qualifiers
Age ≥18 years.
Ability to provide informed consent and comply with study procedures.
Must not be pregnant or breastfeeding.
Negative pregnancy test required for women of childbearing potential.
Disqualifiers
Participants who have exceeded NRC regulation for annual radiation exposure from prior research-related scans, including this study (50 mSv total).
More than four prior enrollments in this study.
Participants with severe claustrophobia, chronic pain, or musculoskeletal conditions that prevent completion of the PET scan
Medication & Prior Treatment Exclusions
Trial design
Treatments tested in this trial
- Piflufolastat F18
Treatment groups
200 Participants
are divided into 1 treatment groupSponsors and collaborators
Akiva Mintz
Lead sponsor
Nuclear Imaging Institute
Sponsor institution
Source ClinicalTrials.gov